封面
市场调查报告书
商品编码
1854024

皮肤科合作与许可协议(2016-2025)

Dermatology Collaboration and Licensing Deals 2016-2025

出版日期: | 出版商: Current Partnering | 英文 250+ Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

"皮肤病学合作与许可协议" 报告以前所未有的方式,全面深入地展现了全球领先的生物製药公司达成的皮肤病学交易。

本报告详细介绍了2016年至2025年间达成的474项皮肤科交易。

本报告提供了交易双方已公布的付款条款。这些数据有助于深入了解付款条款和其他交易条款。

了解潜在合作伙伴协商条款的弹性,有助于深入了解谈判过程,以便更好地预期谈判结果。虽然许多中小企业会寻求详细的付款条款,但魔鬼藏在细节里,尤其是在付款方式和权利转让方面。

本报告全面列出了自 2016 年以来在 "当前协议" 交易和合作资料库中记录的所有合作与许可协议,并附有财务条款(如有),以及公司及其合作伙伴向美国证券交易委员会提交的实际许可协议文件的在线链接。

本报告第一章探讨了皮肤病学领域的交易和商业活动。第一章为报告的引言,第二章分析了皮肤病学领域的交易趋势。

第三章介绍了皮肤病学领域已达成交易的财务条款和发展阶段。交易按总价值、首付款、里程碑付款和特许权使用费率进行分类。

第四章回顾了在皮肤病学交易中最活跃的 25 家生物製药公司。 对于已公开披露协议的交易,Current Agreements Deals & Alliances 数据库提供在线链接,方便查阅这些协议。

第五章对自 2016 年以来签署和公布的、且有协议文件可供查阅的皮肤病学交易进行了全面深入的回顾。每个交易标题都透过网路连结指向实际的线上协议文件,方便读者随时查阅每份协议。

第六章提供了一个按目标公司分类的皮肤病学交易综合目录。

本书还包含大量图表,展示了自 2016 年以来皮肤病学领域的交易趋势和活动。

此外,此综合交易目录按公司名称(A-Z)和技术类型进行组织。每个交易标题都透过网路连结指向线上交易记录,并在可用的情况下包含协议文件,方便读者根据需要轻鬆存取每份协议文件。

主要优势

皮肤科合作研究和授权协议为读者提供以下主要优势:

  • 了解自 2016 年以来的交易趋势
  • 查看皮肤科合作和许可交易
  • 基准分析 - 确定交易市场价值
  • 财务条款 - 预付款、里程碑付款、特许权使用费
  • 按公司 A-Z、治疗领域和技术类型分类的交易目录
  • 主要交易价值
  • 最活跃的交易撮合者
  • 确定每笔交易的资产和交易条款
  • 存取合约文件 - 深入了解交易结构
  • 尽职调查 - 评估拟议交易条款是否适合您的合作伙伴
  • 节省数百小时的研究时间

范围

  • 皮肤病学合作和授权协议旨在帮助您深入了解以下内容:全球领先生物製药公司的皮肤病学趋势和交易结构。

皮肤科合作和许可协议包括:

  • 生物製药产业皮肤科交易趋势
  • 合作与授权交易结构概述
  • 涵盖製药和生物技术的皮肤病学交易记录目录
  • 主要皮肤病学交易
  • 最活跃的皮肤科许可公司

皮肤病学合作和许可交易清单列出了可用的交易。

  • 公司 A-Z
  • 交易金额
  • 治疗领域
  • 技术类型
  • 每个交易标题都透过网路连结连结到实际的线上交易记录,方便存取合约文件(如有)。
  • 皮肤病学合作与许可协议提供对交易记录(包括合约文件)的全面存取权。

对合约文件的分析有助于进行尽职调查,包括:

  • 具体授予或选择哪些权利?
  • 根据合同,合作伙伴实际获得哪些权益?
  • 授予了哪些排他性权利?
  • 合约的付款结构是什么?
  • 如何对销售和付款进行审计?
  • 合约期限是多久?
  • 如何定义合约的关键条款?
  • 如何处理并拥有知识产权?
  • 谁负责商业化?
  • 谁负责开发、供应和生产?
  • 如何管理保密性和资讯揭露?
  • 如何解决争议?
  • 在什么情况下可以终止合约?
  • 如果所有权发生变更,会发生什么事?
  • 已达成哪些转许可或分包条款?
  • 公司坚持哪些标准条款?
  • 哪些标准条款似乎因合作伙伴和交易类型而异?
  • 公司主张其在契约法方面享有哪一个管辖权?

目录

摘要整理

第一章:引言

第二章:皮肤科交易趋势

  • 引言
  • 历年皮肤科合作状况
  • 按交易类型划分的皮肤科合作
  • 按行业划分的皮肤科合作
  • 依研发阶段划分的皮肤科合作
  • 按技术类型划分的皮肤科合作
  • 依治疗适应症划分的皮肤科合作

第三章:皮肤科合作的财务条款

  • 引言
  • 揭露皮肤科合作的财务条款
  • 皮肤科的核心价值合作关係
  • 皮肤科交易预付款
  • 皮肤科交易里程碑付款
  • 皮肤科特许权使用费率

第四章 - 皮肤科关键交易及交易撮合者

  • 引言
  • 皮肤科合作领域最活跃的机构
  • 最活跃的皮肤科交易撮合者名单
  • 以价值排名的顶级皮肤科交易

第五章:皮肤科合约文件目录

  • 引言
  • 皮肤科合作协议及可用合约

第六章:依治疗标靶划分的皮肤科交易

  • 引言
  • 依治疗标靶划分的皮肤科交易
  • 交易目录
  • 交易目录- 皮肤病学交易(按公司、亚利桑那州、2016-2025 年)
  • 交易目录 - 按技术类型划分的皮肤病学交易(2016-2025 年)
  • 交易类型定义
  • 关于研究公司
  • 当前合作伙伴关係
  • 当前协议
  • 按目前合作伙伴关係划分的当前报告标题
简介目录
Product Code: CP2216

Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 474 dermatology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in dermatology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the dermatology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in dermatology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of dermatology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of dermatology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in dermatology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Dermatology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse dermatology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Dermatology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of dermatology trends and structure of deals entered into by leading biopharma companies worldwide.

Dermatology Collaboration and Licensing Deals includes:

  • Trends in dermatology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of dermatology deal records covering pharmaceutical and biotechnology
  • The leading dermatology deals by value
  • Most active dermatology licensing dealmakers

In Dermatology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Dermatology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in dermatology dealmaking

  • 2.1. Introduction
  • 2.2. Dermatology partnering over the years
  • 2.3. Dermatology partnering by deal type
  • 2.4. Dermatology partnering by industry sector
  • 2.5. Dermatology partnering by stage of development
  • 2.6. Dermatology partnering by technology type
  • 2.7. Dermatology partnering by therapeutic indication

Chapter 3 - Financial deal terms for dermatology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for dermatology partnering
  • 3.3. Dermatology partnering headline values
  • 3.4. Dermatology deal upfront payments
  • 3.5. Dermatology deal milestone payments
  • 3.6. Dermatology royalty rates

Chapter 4 - Leading dermatology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in dermatology partnering
  • 4.3. List of most active dealmakers in dermatology
  • 4.4. Top dermatology deals by value

Chapter 5 - Dermatology contract document directory

  • 5.1. Introduction
  • 5.2. Dermatology partnering deals where contract document available

Chapter 6 - Dermatology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by dermatology therapeutic target
  • Deal directory
  • Deal directory - Dermatology deals by company A-Z 2016 to 2025
  • Deal directory - Dermatology deals by technology type 2016 to 2025
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Dermatology partnering since 2016
  • Figure 2: Dermatology partnering by deal type since 2016
  • Figure 3: Dermatology partnering by industry sector since 2016
  • Figure 4: Dermatology partnering by stage of development since 2016
  • Figure 5: Dermatology partnering by technology type since 2016
  • Figure 6: Dermatology partnering by indication since 2016
  • Figure 7: Dermatology deals with a headline value
  • Figure 8: Dermatology deals with upfront payment values
  • Figure 9: Dermatology deals with milestone payment
  • Figure 10: Dermatology deals with royalty rates
  • Figure 11: Active dermatology dealmaking activity since 2016
  • Figure 12: Top dermatology deals by value since 2016